Jesse J Corry1,2, Ganesh Asaithambi3,4, Arif M Shaik3,4, Jeffrey P Lassig5,4, Emily H Marino6,7, Bridget M Ho6,7, Amy L Castle3,4, Nilanjana Banerji6,7, Megan E Tipps6,7. 1. John Nasseff Neuroscience Specialty Clinic, United Hospital Part of Allina Health, 310 Smith Ave N, MR 64440, Ritchie Building, Suite 440, Saint Paul, MN, 55102, USA. Jesse.Corry@allina.com. 2. Department of Neurosciences, United Hospital Part of Allina Health, Saint Paul, MN, USA. Jesse.Corry@allina.com. 3. John Nasseff Neuroscience Specialty Clinic, United Hospital Part of Allina Health, 310 Smith Ave N, MR 64440, Ritchie Building, Suite 440, Saint Paul, MN, 55102, USA. 4. Department of Neurosciences, United Hospital Part of Allina Health, Saint Paul, MN, USA. 5. Midwest Radiology, United Hospital Part of Allina Health, Saint Paul, MN, USA. 6. Neuroscience Research, United Hospital Part of Allina Health, Saint Paul, MN, USA. 7. Neuroscience Research, Abbott Northwestern Hospital, Minneapolis, MN, USA.
Abstract
BACKGROUND: Perihematomal edema (PHE) growth in intracranial hemorrhage (ICH) is a biomarker for worse outcomes. Although the management of PHE is potentially beneficial for ICH patients, there is currently no proven clinical therapy that both reduces PHE and improves outcomes in this population. OBJECTIVE: To examine the safety and tolerability of conivaptan, a non-peptide vasopressin (AVP) receptor antagonist, for the management of PHE in ICH patients. METHODS: We performed a single-center, open-label, phase I study in seven patients with ICH at risk for developing PHE. Conivaptan (20 mg) was administered every 12 h for 2 days, along with the standard ICH management. Electrolyte levels, renal and cardiac function, and vital signs were monitored throughout treatment. Neurological status, ICH, and PHE volumes were assessed at study baseline, 24 h, 72 h, and 7 days from the first conivaptan administration, as well as at the 3-month follow-up. RESULTS: Conivaptan was well tolerated in our patients. We observed the expected increase in sodium levels following conivaptan administration (p = 0.01), with no change in cardiac or renal function. All patients survived to follow-up, and adverse event rates were comparable with those of the neurocritical care unit overall. CONCLUSIONS: These data indicate that conivaptan can be safely administered to ICH patients and support further clinical investigation into the efficacy of this drug for ICH treatment. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov; NCT03000283, 22 December 2016.
BACKGROUND:Perihematomal edema (PHE) growth in intracranial hemorrhage (ICH) is a biomarker for worse outcomes. Although the management of PHE is potentially beneficial for ICHpatients, there is currently no proven clinical therapy that both reduces PHE and improves outcomes in this population. OBJECTIVE: To examine the safety and tolerability of conivaptan, a non-peptide vasopressin (AVP) receptor antagonist, for the management of PHE in ICHpatients. METHODS: We performed a single-center, open-label, phase I study in seven patients with ICH at risk for developing PHE. Conivaptan (20 mg) was administered every 12 h for 2 days, along with the standard ICH management. Electrolyte levels, renal and cardiac function, and vital signs were monitored throughout treatment. Neurological status, ICH, and PHE volumes were assessed at study baseline, 24 h, 72 h, and 7 days from the first conivaptan administration, as well as at the 3-month follow-up. RESULTS:Conivaptan was well tolerated in our patients. We observed the expected increase in sodium levels following conivaptan administration (p = 0.01), with no change in cardiac or renal function. All patients survived to follow-up, and adverse event rates were comparable with those of the neurocritical care unit overall. CONCLUSIONS: These data indicate that conivaptan can be safely administered to ICHpatients and support further clinical investigation into the efficacy of this drug for ICH treatment. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov; NCT03000283, 22 December 2016.
Authors: Zachary Grunwald; Lauren A Beslow; Sebastian Urday; Anastasia Vashkevich; Alison Ayres; Steven M Greenberg; Joshua N Goldstein; Audrey Leasure; Fu-Dong Shi; Kristopher T Kahle; Thomas W K Battey; J Marc Simard; Jonathan Rosand; W Taylor Kimberly; Kevin N Sheth Journal: Neurocrit Care Date: 2017-04 Impact factor: 3.210
Authors: Mark D Haley; Barbara A Gregson; W Andrew Mould; Daniel F Hanley; Alexander David Mendelow Journal: Stroke Date: 2018-01-10 Impact factor: 7.914
Authors: Kevin N Sheth; W Taylor Kimberly; Jordan J Elm; Thomas A Kent; Pitchaiah Mandava; Albert J Yoo; Götz Thomalla; Bruce Campbell; Geoffrey A Donnan; Stephen M Davis; Gregory W Albers; Sven Jacobson; J Marc Simard; Barney J Stern Journal: Stroke Date: 2013-11-05 Impact factor: 7.914
Authors: Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Alastair J S Webb; Natalie L Ullman; Tim C Morgan; John Muschelli; Joshua Kornbluth; Issam A Awad; Stephen Mayo; Michael Rosenblum; Wendy Ziai; Mario Zuccarrello; Francois Aldrich; Sayona John; Sagi Harnof; George Lopez; William C Broaddus; Christine Wijman; Paul Vespa; Ross Bullock; Stephen J Haines; Salvador Cruz-Flores; Stan Tuhrim; Michael D Hill; Raj Narayan; Daniel F Hanley Journal: Stroke Date: 2015-08-04 Impact factor: 7.914
Authors: Jalal K Ghali; Michael J Koren; James R Taylor; Esther Brooks-Asplund; Kaisheng Fan; Walker A Long; Neila Smith Journal: J Clin Endocrinol Metab Date: 2006-03-07 Impact factor: 5.958
Authors: Darin B Zahuranec; Lynda D Lisabeth; Brisa N Sánchez; Melinda A Smith; Devin L Brown; Nelda M Garcia; Lesli E Skolarus; William J Meurer; James F Burke; Eric E Adelman; Lewis B Morgenstern Journal: Neurology Date: 2014-05-16 Impact factor: 9.910
Authors: A David Mendelow; Barbara A Gregson; Elise N Rowan; Gordon D Murray; Anil Gholkar; Patrick M Mitchell Journal: Lancet Date: 2013-05-29 Impact factor: 79.321
Authors: Kathryn N Kearns; Natasha Ironside; Min S Park; Bradford B Worrall; Andrew M Southerland; Ching-Jen Chen; Dale Ding Journal: Neurocrit Care Date: 2021-08-02 Impact factor: 3.210